How we treat patients with metastatic HER2-positive breast cancer.

ESMO Open · 2022 · PMC8741455 · PMID 34995893

Europe PMC DOI

hedged sentences

0.0071

closest p · 0.1× alpha

0.0071

boldest claim

The sentences

a strong trendP = 0.0071actually significant

A strong trend for OS benefit was also observed favoring the T-DXd arm (HR 0.56, 95% CI 0.36-0.86, P = 0.0071).

also in 5,725 other papers

showed a trendno p-value reported

T-DXd significantly improved progression-free survival and showed a trend towards improved overall survival, establishing this agent as preferred second-line therapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.